The enhanced knowledge that certain diseases are caused by the inheritance of single functionally defective gene has laid the idea of gene therapy.
Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights
- Global Market Gene Therapy Landscape USD 24 Billion Opportunity
- Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies
- Gene Therapy Products Dosage & Price Analysis
- Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials
- Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company
- Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target
- Global & Regional Market Insight
For Report Sample Contact neeraj@kuickresearch.com
The enhanced knowledge that certain diseases are caused by the inheritance of single functionally defective gene has laid the idea of gene therapy. Gene therapy is a novel treatment modality which involves inserting one or more corrective genes that have been designed in the laboratory into patient cells to treat diseases. The novel therapy aims at influencing the course of various genetic and acquired disorders at the genetic level whereas cell therapy targets various diseases at the cellular level i.e. by restoration of a certain cell population or using cells as carriers of therapeutic carrier.
Till date, there are two types of gene therapies including ex vivo and in vivo. Ex vivo gene therapy removes cells from the patient, introduces new genetic material, packaged in a delivery vehicle and is then the cells are returned to patients. In contrast, in vivo gene therapy involves direct intravenous infusion of the vector into the bloodstream or injection a target organ like the eye. The in vivo category is predicted to lead the market for gene therapy in the coming years, under the type segment. Unlike the ex vivo method, it causes no harm to the host cells and thus, does not disrupt their functioning.
Recently, the demand for gene therapy has been significantly increased which is primarily fueled by the potential benefits of chimeric antigen receptor T-cell therapy. Chimeric Antigen Receptor (CAR) T cell therapy is one such novel therapeutic treatment which comprises reengineering cancer patient’s white blood cells (WBC) to fight the malignant cells by recognizing them. During this therapy, the person’s T cells are extracted, preciously reformed and then inserted again to the person’s body where the restructured cell multiply and target cancer cells. Currently, five CAR-T cell therapy products have been approved which is recognized as vastly effective in patients with blood cancer or hematologic cancer specifically for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas.
As per our report findings, the global gene therapy market is expected to surpass US$ 20 Billion by 2028. The expanding arena of advanced therapies and gene delivery technologies has created an increasingly competitive dynamic where a substantial number of market players are engaged in the commercialization of their gene therapy products. Furthermore, companies are engaged in strategic alliances to boost their offerings in the space, which is anticipated to intensify the market competition during the forecast period. For instance, in March 2020, Rexenbio and Ultragenyx Pharmaceutical collaborated for the use of the NAV technology platform. Other key players working in market includes Oxford Biomedica, Sanofi, Bristol Meyer Squibb, Bluebird Bio, Novartis, Transgene, and several others.
US held the largest share in the market in 2020 and this trend is expected to continue in forthcoming year. This is mainly attributed to the increasing prevalence of rare diseases and cancer and presence of several leading key players in the region. In addition, regulatory authorities in the region are rapidly approving gene therapy products, thereby fueling the expansion of the market. Apart from this, US FDA have provide orphan drug designations or breakthrough therapy designations to wide range of gene therapy products which are expected to enter the market in forthcoming years. For instance, in November 2021, US FDA has granted orphan drug designation to RGX202, which is one time experimental gene therapy for the management of Duchenne muscular dystrophy. Europe held the second spot in the market which is mainly due to increase investments in countries including UK, Germany, and others. Additionally, European companies are committed to expanding their global distribution of goods across multiple regulatory bodies.
Contact:
Neeraj Chawla
Research Head
+919810410366